ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera

What is an MPN Specialist?
December 1, 2017
Celgene MPN drug Fedratinib
Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline
January 8, 2018

ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera

Dr Mascarenhas presenting at ASH 2017 on Nutlin

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV).

Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination with pegylated interferon, said John Mascarenhas, MD, at the 2017 ASH Annual Meeting.  Click the link below for the full story:

 

 

 

Comments are closed.

WordPress Security